ClinicalTrials.gg

Program

VG712

A development code.

Its studies are mostly in Mycosis Fungoides, led by Virogen Biotechnology.

Furthest: phase 2, since Mar 20, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Virogen Biotechnology11 open or runningphase 2since Mar 20, 2026Mar 20, 2026Dec 30, 2030phase 2 · NCT07529405

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2026First study: phase 2 study in Mycosis FungoidesFirst studyNCT07529405 · 386 planned · United States

Ahead

  1. Dec 30, 2030Primary completion: phase 2 study in Mycosis FungoidesNCT07529405

TargetBeta

CD3E →read by rule
“VG712 is a recombinant anti-CD3 immunotoxin designed to selectively deplete CD3-positive T cells.”study text, by rule · the study

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07529405Mycosis Fungoides · United States2Not yet recruitingDec 30, 2030386

How it is read

Names in the registry

  • “VG712”, 1 entry

Codes read as this program: VG712.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.